AiCure secures $12.25M Series A for its AI platform

AiCure medication adherence

AiCure, which uses artificial intelligence to improve treatments and patients’ health, has closed a Series A financing totaling $12.25 million. New Leaf Venture Partners led the round, with participation from Pritzker Group Venture Capital, Tribeca Venture Partners, and Biomatics Capital. As part of the deal, New Leaf managing director Vijay Lathi has joined the company’s board of directors.

AiCure’s mobile software-as-a-service (SaaS) platform uses machine learning, computer vision, and big data to visually confirm medication ingestion, which is fundamental to both clinical trials and clinical care.

AiCure has gained significant traction from pharmaceutical companies, government institutions and payers.“Accurately understanding patient behavior through artificial intelligence defines a new category of medication adherence monitoring,” says Adam Hanina, CEO of AiCure.

Before this financing, AiCure along with participating academic collaborators scored a $7 million grant from the National Institutes of Health (NIH) funding to develop a platform that would “significantly impact drug research and therapy.” It was during that process when AiCure’s technology has been validated across very different patient populations, against drug levels in blood samples.

Beyond the NIH, AiCure has gained significant traction from pharmaceutical companies, government institutions and payers which are looking for best ways to monitor medication adherence and optimize treatment models.